Web-based site provides access to the HeartCheck(TM) PEN by Canadians who are without easy access to pharmacies
TORONTO, ON / ACCESSWIRE / July 28, 2014 / CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company"), a global medical provider of electrocardiogram ("ECG") acquisition and management software solutions, today announced a distribution agreement with Toronto-based PHARMACY.CA, for internet-based sales of the HeartCheck(TM) ECG PEN device.
The agreement designates PHARMACY.CA as an authorized retailer for the sale of the HeartCheck(TM) PEN in Canada. PHARMACY.CA has been providing Canadians with reliable solutions to purchase over-the-counter (OTC), prescription and specialty medical products found in conventional pharmacy stores without leaving their home, for the past 15 years.
"Certainly a pharmacy centric retail model has been identified as an important market channel for us," noted Etienne Grima, CEO of CardioComm Solutions Inc. "There is a growing trend in consumers seeking tools that can help them monitor their own health. Increasingly, the pharmacist has become a trusted partner and often a first port of call for persons unsure if they should see their physician. Access to a device like the HeartCheck(TM) PEN through the local pharmacist adds an important new dimension of service that pharmacists can provide and a new measure of convenience for consumers who can now obtain this device through an online purchase."
"CardioComm Solutions continues to implement its pharmacy-based retail sales strategy for the handheld HeartCheck(TM) PEN ECG device in Canada, with the roll out governed heavily by the pharmacy banner groups we are working with," said Simi Grosman, a member of CardioComm Solutions' Board of Directors. "Internet-based sales are an important part of this strategy and PHARMACY.CA is therefore a very logical choice and synergistic partner for us."
The Company reports that the timing and selection of locations where the HeartCheck(TM) PEN product will be made available will be a phased process. During this time, PHARMACY.CA will provide a trusted, web-based sales opportunity with no timing barriers.
As the pharmacy banner role out occurs, availability of the HeartCheck(TM) PEN through PHARMACY.CA will complement the process and allow people who see the device advertised as a pharmacy OTC item, to purchase the HeartCheck(TM) PEN online should their local pharmacy not have the HeartCheck(TM) PEN on the store shelf. This might often be the case in rural/satellite communities who will now be able to purchase the device online and then proceed to have their ECG read by a doctor or technician from a remote location using the Company's patent pending SMART Monitoring ECG service.
"We are very interested in adding the HeartCheck(TM) PEN ECG device to our online products. This represents a new and innovative home-health monitoring solution that we believe will be of interest to our national customer base. With the planned promotion of the device likely to focus on large urban pharmacy operations, PHARMACY.CA will be able to expand access to those Canadians who may not be provided an opportunity to make a purchase at a local pharmacy," added Scott Leslie, President of PHARMACY.CA.
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Ontario, Canada, with offices in Victoria, B.C.
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
In evaluating these statements, readers should: specifically consider risks discussed under the heading "Risk Factors" in the Company's Annual Information Form, available at www.sedar.com; not to place undue reliance on forward-looking statements and forward-looking information; be aware the Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this Annual Information Form other than as required by applicable laws (including without limitation Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: CardioComm Solutions, Inc.